Zishan Yang

Dr. Zishan Yang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2024 in Microbial Cell Factories
Verified
Journal Article
Open access
PDF file
SQShaoju Qian
Shaoju Qian
RLRuixue Li
Ruixue Li
YHYeqing He
Yeqing He
HWHexi Wang
Hexi Wang
DZDanqiong Zhang
Danqiong Zhang
ZYZishan Yang
Zishan Yang
Herpes simplex virus type 1 (HSV-1) is a major cause of viral encephalitis, genital mucosal infections, and neonatal infections. Lactococcus lactis (L. lactis) has been proven to be an effective vehicle for delivering protein antigens and stimulating both mucosal and systemic immune responses. In this study, we constructed a recombinant L. lactis system expressing the protective antigen glycoprotein D (gD) of HSV-1. To improve the stability and persistence of antigen stimulation of the local mucosa, we inserted the immunologic adjuvant interleukin (IL)-2 and the Fc fragment of IgG into the expression system, and a recombinant L. lactis named NZ3900-gD-IL-2-Fc was constructed. By utilizing this recombinant L. lactis strain to elicit an immune response and evaluate the protective effect in mice, the recombinant L. lactis vaccine induced a significant increase in specific neutralizing antibodies, IgG, IgA, interferon-γ, and IL-4 levels in the serum of mice. Furthermore, in comparison to the mice in the control group, the vaccine also enhanced the proliferation levels of lymphocytes in response to gD. Moreover, recombinant L. lactis expressing gD significantly boosted nonspecific immune reactions in mice through the activation of immune-related genes. Furthermore, following the HSV-1 challenge of the murine lung mucosa, mice inoculated with the experimental vaccine exhibited less lung damage than control mice. Our study presents a novel method for constructing a recombinant vaccine using the food-grade, non-pathogenic, and non-commercial bacterium L. lactis. The findings indicate that this recombinant vaccine shows promise in preventing HSV-1 infection in mice.

29 October 2025 in International Immunopharmacology
Verified
Journal Article
Open access
YHYixuan Han
Yixuan Han
SWSuli Wang
Suli Wang
CLChenyang Li
Chenyang Li
SZShenglan Zhang
Shenglan Zhang
XGXiaotong Geng
Xiaotong Geng
ZYZishan Yang
Zishan Yang
Interleukin-27 (IL-27), an Interleukin-12 (IL-12) family heterodimeric cytokine, plays a central yet complex role in immunoregulation within the intestinal mucosa, where its context-dependent actions can promote both protective and pathogenic outcomes. Although its cellular sources, receptor structure (IL-27Rα/gp130 complex), and involvement in regulating key immune cells (e.g., T-cell subsets, macrophages, neutrophils) and epithelial functions are established, the precise mechanisms underlying its paradoxical effects-balancing homeostasis with inflammation-remain incompletely resolved. This review synthesizes current understanding of IL-27 biology to clarify its multifaceted role. Crucial insights into these dual functions have emerged from preclinical models, including murine colitis (e.g., DSS-, TNBS-induced), enteric infection (e.g., Toxoplasma gondii, Citrobacter rodentium), and colorectal cancer models. These studies demonstrate that IL-27 critically orchestrates gut immunity, maintaining homeostasis through antimicrobial defense and barrier enhancement while suppressing immunopathology. Conversely, its dysregulation drives chronic inflammation and carcinogenesis. Clinically, IL-27 expression correlates with disease activity in inflammatory bowel disease (IBD), colorectal cancer (CRC), and infections, highlighting its biomarker potential. Consequently, targeting the IL-27 pathway presents promising therapeutic avenues: augmenting signaling may mitigate IBD hyperinflammation, while inhibition could bolster antitumor immunity or resolve infection-driven pathology. Future research must prioritize defining context-specific IL-27 functions, optimizing delivery strategies, and integrating IL-27 targeting with existing biologics to translate its immunomodulatory potential into novel therapies for intestinal diseases.

4 July 2025 in Biochemical Pharmacology
Verified
Journal Article
Closed access
TZTiesuo Zhao
Tiesuo Zhao
LLLirui Liang
Lirui Liang
DTDongli Tang
Dongli Tang
XCXurui Chai
Xurui Chai
HJHanyu Jiang
Hanyu Jiang
JHJia Huijie
Jia Huijie

15 April 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SWShanshan Wang
Shanshan Wang
YCYanfang Chen
Yanfang Chen
TYTingting Yang
Tingting Yang
DZDaming Zhang
Daming Zhang
YLYadi Liu
Yadi Liu
ZXZhiqiang Xiao
Zhiqiang Xiao
Background: Psoriasis and metabolic dysfunction–associated fatty liver disease (MAFLD) share pathological features such as chronic inflammation, immune dysregulation, and metabolic disturbance. Increasing evidence suggests biological crosstalk between the two conditions, offering new insights into their shared mechanisms and comanagement. Early-stage MAFLD, characterized by hepatic steatosis without evident inflammation or fibrosis, provides a crucial window for intervention. This study aimed to identify early diagnostic biomarkers linking psoriasis and MAFLD. Methods: Transcriptomic datasets of psoriasis and MAFLD were retrieved from the Gene Expression Omnibus (GEO) database. Weighted gene co-expression network analysis (WGCNA) was used to identify MAFLD-related modules. Shared genes were obtained by intersecting module genes with differentially expressed genes (DEGs) from psoriasis datasets. Machine learning algorithms, including random forest (RF), least absolute shrinkage and selection operator (LASSO), and support vector machine (SVM), were applied to identify hub genes. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis, immune infiltration assessment, Spearman correlation, and experimental validation in psoriasis and MAFLD mouse models. Results: Twenty-nine shared genes were identified and found to be enriched in immune and metabolic pathways. Six hub genes—ADRB2, WNT5A, S100A9, FAM110C, S100A12, and TUBB6—were selected through integrated machine learning analysis and experimental validation. These genes exhibited high diagnostic accuracy and significant correlations with disease severity and immune cell infiltration. Conclusions: This study identified six hub genes—ADRB2, WNT5A, S100A9, FAM110C, S100A12, and TUBB6—as potential cross-disease biomarkers for the comorbidity of psoriasis and MAFLD, and these genes are significantly associated with disease severity. These findings provide new targets for early diagnosis and potential treatment strategies for the comorbidity.

24 August 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
ZXZhishan Xu
Zhishan Xu
DSDingbo Song
Dingbo Song
FHFangqi Hu
Fangqi Hu
QLQiuhan Liang
Qiuhan Liang
MZMengyao Zhang
Mengyao Zhang
ZYZishan Yang
Zishan Yang
Inflammatory bowel disease (IBD) and colorectal cancer (CRC) are heterogeneous intestinal disorders that pose significant threats to human health and share common pathological features, including intestinal mucosal barrier disruption and gut microbiota dysbiosis, in which fucosylation acts as a critical regulatory mediator. Fucosylation is a highly conserved post-translational glycosylation modification involving the enzymatic transfer of fucose residues to glycoproteins and glycolipids. This tightly regulated process plays essential roles in maintaining intestinal homeostasis, mediating host–microbiota interactions and regulating immune responses. This review adopts a physiology-to-pathology framework, delineating fucosylation’s operational principles in healthy intestines and its dysregulation in IBD and CRC. It summarizes the spatial distribution of fucosylation, its regulatory mechanisms, and its roles in disease pathogenesis, and also discusses its potential as a diagnostic biomarker and therapeutic target. Finally, this review highlights future research directions to bridge mechanistic insights with clinical translation, emphasizing the promise of fucosylation in the precision diagnosis and treatment of intestinal disorders.